Literature DB >> 8388386

Characterization of the receptor-binding domain of tetanus toxin.

J L Halpern1, A Loftus.   

Abstract

The carboxyl-terminal half of the heavy chain of tetanus toxin (Hc) contains the domain required for binding to purified gangliosides and neuronal cells. The structural requirements for the interaction of Hc with receptor were studied by generating mutants of Hc with deletions at either the carboxyl or amino terminus and characterizing their binding. A deletion of 10 or more amino acids from the carboxyl terminus resulted in a major loss of Hc binding to purified gangliosides and spinal cord neuronal cells, whereas a deletion of the carboxyl-terminal 5 amino acids did not affect binding. The removal of up to 263 amino acids from the amino terminus did not inhibit binding. Each of the truncated proteins was much more sensitive to trypsin than was full-length Hc, suggesting an alteration in conformation. The receptor binding activity of Hc was not retained in a peptide corresponding to the carboxyl-terminal 20 amino acids. These data suggest that the carboxyl-terminal region of Hc is important for maintaining a conformation necessary for binding to receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388386

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor.

Authors:  J Herreros; G Lalli; G Schiavo
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

2.  Mass spectrometry and non-covalent protein-ligand complexes: confirmation of binding sites and changes in tertiary structure.

Authors:  Sharon J Shields; Olayinka Oyeyemi; Felice C Lightstone; Rod Balhorn
Journal:  J Am Soc Mass Spectrom       Date:  2003-05       Impact factor: 3.109

Review 3.  Neural stem cells redefined: a FACS perspective.

Authors:  Dragan Maric; Jeffery L Barker
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

4.  Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Authors:  Simon N Fewou; Angie Rupp; Lauren E Nickolay; Kathryn Carrick; Kay N Greenshields; John Pediani; Jaap J Plomp; Hugh J Willison
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

5.  Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Authors:  K A Foster; E J Adams; L Durose; C J Cruttwell; E Marks; C C Shone; J A Chaddock; C L Cox; C Heaton; J M Sutton; J Wayne; F C G Alexander; D F Rogers
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

6.  Cell surface-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracis protects against tetanus toxin.

Authors:  S Mesnage; M Weber-Levy; M Haustant; M Mock; A Fouet
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

8.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Characterization of recombinant tetanus toxin derivatives suitable for vaccine development.

Authors:  D Figueiredo; C Turcotte; G Frankel; Y Li; O Dolly; G Wilkin; D Marriott; N Fairweather; G Dougan
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.